US Panel Suggests Stricter Trial Safety Margins for Cerus Corporation (JOBS)

Bookmark and Share

Reuters -- Blood-safety products maker Cerus Corp (CERS.O) said an U.S. advisory committee recommended more stringent safety margins for a late-stage trial of its intercept blood system to treat platelets.

MORE ON THIS TOPIC